These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38711784)

  • 1. Endocrine system-related adverse events associated with PD-1/PD-L1 inhibitors: data mining from the FDA adverse event reporting system.
    Shi H; He Y; Dan S; Yang L; Wang J; Chen L; Chen Z
    Front Med (Lausanne); 2024; 11():1366691. PubMed ID: 38711784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors.
    Anand K; Sahu G; Burns E; Ensor A; Ensor J; Pingali SR; Subbiah V; Iyer SP
    ESMO Open; 2020 Aug; 5(4):. PubMed ID: 32817069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-1/PD-L1 inhibitor-induced immune thrombocytopenia: A pharmacovigilance study and systematic review.
    Moore DC; Elmes JB; Arnall JR; Strassel SA; Patel JN
    Int Immunopharmacol; 2024 Mar; 129():111606. PubMed ID: 38359661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulmonary Immune-Related Adverse Events of PD-1 Versus PD-L1 Checkpoint Inhibitors: A Retrospective Review of Pharmacovigilance.
    Ebinama U; Sheshadri A; Anand K; Swaminathan I
    J Immunother Precis Oncol; 2023 Nov; 6(4):177-184. PubMed ID: 38143955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
    Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
    J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.
    Chen C; Wu B; Zhang C; Xu T
    Int Immunopharmacol; 2021 Jun; 95():107498. PubMed ID: 33725634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulmonary adverse events associated with hypertension in non-small cell lung cancer patients receiving PD-1/PD-L1 inhibitors.
    Chen J; Wen Y; Chu X; Liu Y; Su C
    Front Pharmacol; 2022; 13():944342. PubMed ID: 36110543
    [No Abstract]   [Full Text] [Related]  

  • 8. Analysis on the risk of myasthenia gravis related to immune checkpoint inhibitors based on the US FDA Adverse Event Reporting System.
    Kong Q; Wang H; Ren X; Zhuo Y; Peng J
    Cancer Med; 2023 Oct; 12(19):19491-19499. PubMed ID: 37724594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ileus in patients treated with immune checkpoint inhibitors: A retrospective, pharmacovigilance study using Food and Drug Administration Adverse Event Reporting System database.
    Gao S; He Z; Zhu J; Liang D; Zhao W; Yang S; Jiang W; Qiu K; Yu X; Wu J
    Pharmacoepidemiol Drug Saf; 2022 Nov; 31(11):1199-1205. PubMed ID: 35689298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database.
    Mikami T; Liaw B; Asada M; Niimura T; Zamami Y; Green-LaRoche D; Pai L; Levy M; Jeyapalan S
    J Neurooncol; 2021 Mar; 152(1):135-144. PubMed ID: 33423151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System.
    Raschi E; Mazzarella A; Antonazzo IC; Bendinelli N; Forcesi E; Tuccori M; Moretti U; Poluzzi E; De Ponti F
    Target Oncol; 2019 Apr; 14(2):205-221. PubMed ID: 30927173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1/PD-L1 inhibitors-associated cardiac adverse events: a retrospective and real-world study based on the FDA Adverse Event Reporting System (FAERS).
    Wang Q; Xiao F; Zeng Y; Zhu Q; Zhang H
    Expert Opin Drug Saf; 2024 Feb; 23(2):257-267. PubMed ID: 37070426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A real-world retrospective study of incidence and associated factors of endocrine adverse events related to PD-1/PD-L1 inhibitors.
    Wang Z; Hu C; Zhang A; Wang X; Zeng D; Long T; Zhu B; Wang Z
    Ann Transl Med; 2023 Feb; 11(4):164. PubMed ID: 36923080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
    Nishijima TF; Shachar SS; Nyrop KA; Muss HB
    Oncologist; 2017 Apr; 22(4):470-479. PubMed ID: 28275115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted to FAERS.
    Ji HH; Tang XW; Dong Z; Song L; Jia YT
    Clin Drug Investig; 2019 Mar; 39(3):319-330. PubMed ID: 30674039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive Evaluation of Anti-PD-1, Anti-PD-L1, Anti-CTLA-4 and Their Combined Immunotherapy in Clinical Trials: A Systematic Review and Meta-analysis.
    Xiang Z; Li J; Zhang Z; Cen C; Chen W; Jiang B; Meng Y; Wang Y; Berglund B; Zhai G; Wu J
    Front Pharmacol; 2022; 13():883655. PubMed ID: 35694260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ocular adverse events in PD-1 and PD-L1 inhibitors.
    Young L; Finnigan S; Streicher H; Chen HX; Murray J; Sen HN; Sharon E
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34226280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
    Barroso-Sousa R; Barry WT; Garrido-Castro AC; Hodi FS; Min L; Krop IE; Tolaney SM
    JAMA Oncol; 2018 Feb; 4(2):173-182. PubMed ID: 28973656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk monitoring and pharmacovigilance of programmed cell death protein 1 / programmed cell death 1 ligand 1 in cancer patients after solid organ transplantation.
    Mei L; Li S; Fan Q; Zhao B; Mei D; Took R; Zhen J
    Therapie; 2023; 78(4):385-392. PubMed ID: 36481226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
    Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
    BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.